Papillary Thyroid Cancer is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Papillary Thyroid Cancer have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Papillary Thyroid Cancer compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Papillary Thyroid Cancer overview
Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 75% to 85% of all cases. It affects more women than men and can occur at any age, but especially between 30 and 50 years old. PTC is usually slow-growing and well-differentiated, meaning it resembles normal thyroid cells. However, it can also spread to the lymph nodes in the neck or other parts of the body. The main symptom of PTC is a painless lump or nodule on the thyroid gland, which can be detected by physical examination or ultrasound. The diagnosis of PTC is confirmed by a fine needle aspiration (FNA) biopsy, which samples cells from the nodule for microscopic analysis. The treatment of PTC depends on the size, stage, and aggressiveness of the tumor, but it usually involves surgery to remove the thyroid gland (thyroidectomy) and radioactive iodine therapy to destroy any remaining cancer cells. PTC has a very good prognosis, with a survival rate of over 90% after 10 years.
For a complete picture of PTSR and LoA scores for drugs in Papillary Thyroid Cancer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
